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Abstract
Background
Adverse Drug Reactions (ADRs) are a major clinical and public health problem world-wide.
The prompt reporting of suspected ADRs to regulatory authorities to activate drug safety
surveillance and regulation appears to be the most pragmatic measure for addressing the
problem. This paper evaluated a pharmacovigilance (PV) training model that was designed
to improve the reporting of ADRs in public health programs treating the Human Immunodefi-
ciency Virus (HIV), Tuberculosis (TB) and Malaria.
Methods
A Structured Pharmacovigilance and Training Initiative (SPHAR-TI) model based on the
World Health Organization accredited Structured Operational Research and Training Initia-
tive (SOR-IT) model was designed and implemented over a period of 12 months. A prospec-
tive cohort design was deployed to evaluate the outcomes of the model. The primary
outcomes were knowledge gained and Individual Case Safety Reports (ICSR) (completed
adverse drug reactions monitoring forms) submitted, while the secondary outcomes were
facility based Pharmacovigilance Committees activated and health facility healthcare work-
ers trained by the participants.
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Results
Fifty-five (98%) participants were trained and followed up for 12 months. More than three
quarter of the participants have never received training on pharmacovigilance prior to the
course. Yet, a significant gain in knowledge was observed after the participants completed a
comprehensive training for six days. In only seven months, 3000 ICSRs (with 100% com-
pleteness) were submitted, 2,937 facility based healthcare workers trained and 46 Pharma-
covigilance Committees activated by the participants. Overall, a 273% increase in ICSRs
submission to the National Agency for Food and Drug Administration and Control (NAF-
DAC) was observed.
Conclusion
Participants gained knowledge, which tended to increase the reporting of ADRs. The
SPHAR-TI model could be an option for strengthening the continuous reporting of ADRs in
public health programs in resource limited settings.
Background
Adverse Drug Reactions (ADRs) have emerged as a major clinical and public health problem
responsible for approximately 5 to 35% of hospital admissions in both developed and develop-
ing countries [1–7]. In the United States and Europe, ADRs are among the top ten causes of
mortality as well as increasing the cost of care [4, 8, 9 and 10]. In African countries, the intro-
duction of antiretroviral therapy (ART) for the control of HIV/AIDS has led to an upsurge in
the cardio-metabolic disorders such as type 2 diabetes mellitus and hypertension. Anti-retrovi-
ral drugs–the primary agents in ART, are largely responsible for the rise in cardio-metabolic
disorders in sub-Saharan Africa according to some authors [11, 12]. Similarly, the treatment of
Drug Resistant Tuberculosis (DRTB) with Second line Anti-tuberculosis drugs (SLDs) is driv-
ing the rise of mental illnesses (psychosis), loss of hearing (ototoxicity) and kidney damage in
some countries [13].
Prompt reporting of ADRs to drug regulatory bodies is an important drug safety measure
but under-reporting is a major challenge even in developed countries with adequate human
and material resources to tackle the problem [4, 8, 9 and 10]. A systematic review of 37 studies
by Hazell and Shakir found a median under-reporting rate of 94% [14]. Many factors are asso-
ciated with the under-reporting of ADRs [15]; the commonest factors frequently cited in most
of the studies are healthcare workers’ lack of knowledge and poor attitude [16–29]. In a very
recent study; Terblanche et al [30] found that 53.8% of the participants gave not “knowing
how to report” ADRs as the reason discouraging the reporting. Interestingly, some studies
have shown that training could address both the poor attitude and the lack of knowledge lead-
ing to increase in the accuracy and rate of reporting of ADRs to regulatory bodies [14, 31].
Prompt reporting is pragmatic and arguably, the best method for drug safety surveillance
[32]. The delay in reporting ADRs can be catastrophic; for example, almost seven million
patients took Fenfluramine before its association with Valvular Heart Disease (VHD) was
reported and the drug withdrawn from the market [33]. Similarly, over 10,000 children in Ger-
many in the early sixties suffered Phocomelia before the causative agent; Thalidomide was
identified and withdrawn from clinical practice [34].
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Public health programs, especially the HIV/AIDS, Tuberculosis and Malaria have the great-
est risk of ADRs because millions of people are treated with a wide range of drugs, some of
which have serious/life threatening adverse reactions [35–38]. In the western countries where
ARVs have been used for many years, cases of rising obesity, weight gain and cardio-metabolic
diseases are persistently being reported in association with the use of ARVs [39–40]. The
demand for drug safety surveillance has therefore become a major consideration in the global
scale up of ART to end HIV/AIDS and TB. For instance, the World Health Organization
(WHO) requires countries adopting the “shorter regimen” in the control of DRTB to institute
active drug safety monitoring (aDSM).
The pharmacovigilance system in Nigeria
Pharmacovigilance systems (PVS) refer to schemes that are established to facilitate the report-
ing of suspected ADRs to national or international bodies responsible for the monitoring of
drug safety and regulations. Countries participating in the international drug monitoring
scheme are required by regulation to collect and submit their reports to the International Drug
Monitoring Center in Geneva.
Nigeria joined the International Drug Monitoring Scheme in 2004 and became the 74th
member country. The National Agency for Food and Drug Administration and Control
(NAFDAC)–the body responsible for drug safety and regulation in Nigeria, thereafter, devel-
oped a National Pharmacovigilance Policy and instituted an administrative structure, consist-
ing of the National Pharmacovigilance Center (NPC) in Abuja and Zonal Pharmacovigilance
Centers (ZPC) in each of the six geopolitical regions of the country.
NAFDAC also instituted the National Pharmacovigilance System which involves signal
detection, collection, collation and analysis of ADRs [41]. Organizations or individuals holding
a marketing authorization for marketing medicinal products are mandated to report any sus-
pected ADR associated with the product they are authorized to market [41]. Healthcare pro-
viders (pharmacists, doctors and nurses) are also required by the government to report
suspected ADRs, although this is not mandatory [41] as is the case in Sweden, France and Italy
[42].
The primary tool for reporting ADRs in Nigeria is a structured in-take form known as the
“Adverse Drug Reactions Form” (ADR Form) (Figure A in S1 File) available at https://www.
nafdac.gov.ng. This form is similar to the United Kingdom’s Yellow Card and has five major
sections, which must all be accurately completed. A fully completed ADR form is known as the
“Individual Case Safety Report” (ICSR).
The quality of an ICSR is directly proportional to the amount of clinically relevant informa-
tion that is included [43–46]. On this basis, an ICSR with 100% completeness is expected to
have the highest quality provided that the information included in all the sections is accurate.
In Nigeria, poor quality ICSRs are usually quarantined by the NPC as they cannot be sent to
the International Drug Monitoring Center in Uppsala, Sweden.
A typical ICSR provides the following information:
a. Patient details (name, age, sex and weight)
b. Adverse drug reaction (description, date reaction started and stopped and outcome–recov-
ered fully, congenital abnormality, recovered with abnormality, life threatening and death)
c. Suspected drug (brand and generic names, batch number, NAFDAC number, expiry date)
d. Concomitant medicines (all medicines taken in the last three months)
e. Source of report
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The reporting of ADRs to NAFDAC follows two major steps:
a. Accurate completion of the ADR forms when a suspected ADR is observed by healthcare
providers or reported by a patient during routine treatment of health conditions. Marketing
Authorization Holders (MAH) are also expected to complete the ADR forms when sus-
pected ADR are reported to them by patients, health institutions or the healthcare workers
within and outside the country.
b. Dispatch the ICSRs to the NPC in Abuja.
The ICSRs are dispatched to the NPC in Abuja through different means; the frequently
used method is surface mail posting of the ICSRs to the NPC by the health facilities or visiting
the health facilities by the NAFDAC designated staff to pick up the ICSRs. ICSRs could also be
scanned and sent as “attachment” through emails communication. The NPC validate and ana-
lyze the submitted ICSRs and extract the relevant information into VigiBase–a proprietary
web database (https://www.who-umc.org/vigibase/vigibase/) hosted at the WHO collaborating
center for international drug monitoring in Uppsala, Sweden.
The pervasive problem of under-reporting of adverse drug reactions in
Nigeria
The under-reporting of ADRs in Nigeria has been documented in several studies [47–50].
According to NAFDAC, only 16,500 ICSRs out of 80,000 ADR Forms distributed nation-wide
for 12 years (2004 to 2016), were submitted back to NAFDAC [51]. This is equivalent to sub-
mitting only 1,375 ICSRs per year. The WHO criteria for adequate reporting of ADRs are 200
reports per million inhabitants per year [52]. With a population of 170 million inhabitants in
2016, at least 34,000 ICSRs should have been submitted to NAFDAC instead of the 1,375
ICSRs. Furthermore, Nigeria had 323,941healthcare workers [53–54] (consisting of Physicians,
Nurses, Midwives, Pharmacists, Pharmacy-technicians, Radiographers, Medical Laboratory
Scientists and Community Health Officers), [55–56] according to the 2005–2007 report of the
National Professional Medical/Health Regulatory bodies. In 2015, NAFDAC reported that
only 1,385 ICSRs (see Figure B in S1 File) were submitted supposedly by over 323,941 workers.
Given the large population of healthcare workers and the overwhelming increase in drug con-
sumption due to the high burden of HIV/AIDS, Tuberculosis and Malaria, submitting only
1,385 ICSRs clearly suggests that Nigeria is facing a major crisis of under-reporting of ADRs.
Ironically, the factors that are undermining the reporting of ADRs in other countries are also
rife in Nigeria and these include lack of knowledge, inaccurate description of ADRs, poor qual-
ity reports and poor compliance to the pharmacovigilance processes (data collection, storage,
management, risk assessment and communication) [14,41,44].
The SPHAR-TI model was designed to address the challenge of under-reporting of ADRs in
Nigeria through capacity building. Until the SPHAR-TI course, majority (71.0%) of the health-
care workers that participated in the course have never received training in pharmacovigilance
but were nonetheless working in public health institutions or hospitals directly treating HIV/
AIDS, Tuberculosis and Malaria through the respective public health disease control programs.
Some studies have reported high prevalence of ADRs emanating from the HIV/AIDS, TB and
Malaria public health programs [13, 35, 37, 38, 39, 40], thus, justifying the SPHARTI model.
The structured pharmacovigilance and Training Initiative model
The SPHAR-TI model (refer to S2 File) was a 12 month modular course, modelled after the
WHO accredited Structured Operational and Training Initiative (SORT-IT) [57,58]. The
Addressing the under-reporting of adverse drug reactions in public health programs
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model incorporated six distinct but inter-related activities, referred to as the SPHAR-TI’s prin-
ciples. These are: a training workshop; participants’ mobilization; monitoring and evaluating
and providing feedback; setting up a reporting system; providing leadership and collaborating
with the government. This paper evaluated the model with the main objective of describing
the outcomes after the first 12 months of implementation.
Methods
This manuscript complies with the STROBE reporting standard for observational studies.
Ethics approval
Ethics approval for the evaluation was given to the Institute of Human Virology Nigeria by the
National Health Research Ethics Committee of Nigeria under the title: “Engaging indigenous
organization to sustain and enhance clinical services for the prevention, care and treatment of
HIV/AIDS in the Federal Republic of Nigeria under the President’s Emergency Plan for AIDS
Relief (PEPFAR)”; Number: NHREC/01/01/2007; dated August 12, 2016.
Setting
The workshop was conducted in the Federal Capital Territory, Abuja but the participants were
selected from health facilities and institutions in the six geopolitical regions of Nigeria. Nigeria
has six geopolitical regions with a population of 170 million inhabitants. These regions include
the North-east, North-west, North-central, South-west, South-east and South-south.
Study population
The study population consisted of health care workers (Nurses, Physicians and Pharmacists)
who were selected for the SPHAR-TI course based on rigorous selection criteria (Table A in
S2 File).
Study design
A prospective cohort design was deployed for the evaluation of the SPHAR-TI model. Partici-
pants that attended the SPHAR-TI’s workshop described in S2 File were followed up for 12
months through internet and telephone communication. Performance was evaluated based on
meeting defined milestones. Bio-demographic characteristics were recorded and participants’
knowledge assessed prior to the workshop. Five days after the workshop, participants’ knowl-
edge was re-assessed without giving them a prior warning they would be re-assessed. ICSRs
were submitted online every three months (31st May, 29th July, 30th September and 30th
November 2016). Data on the number of healthcare workers trained by the participants and
the Pharmacovigilance Committees activated were submitted online not later than 10th
December 2016.
Outcomes of measure
The aim of the model was to improve the reporting of ADRs from both hospitals based and
more importantly, community based public health programs controlling the AIDS epidemic,
Tuberculosis and Malaria. The primary outcomes were knowledge gained and the number of
ICSRs submitted to NAFDAC. We expected to see a significant gain in knowledge and a
remarkable increase in the reporting of ADRs if the model was effective. The secondary out-
comes were the health facility staff trained by the participants through the step-down training
and the Pharmacovigilance Committees activated.
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The secondary outcomes were evaluated because NAFDAC encourages the setting up of
Pharmacovigilance Committees in health facilities as a pragmatic strategy for promoting the
reporting of ADRs. During the workshop, participants were taught and encouraged to step-
down the workshop and activate the committees. We expected the participants to be able to
train others and set up new Pharmacovigilance Committees if the model was effective.
Evaluation of the outcomes of the model
The overall outcome of the model was assessed by comparing the number of ICSRs submitted
by the national health workforce in seven months with the number submitted by the partici-
pants in seven months. The primary and secondary outcomes were evaluated as described
below:
Gain in knowledge. Gain in knowledge was assessed using a structured questionnaire,
consisting of 24 questions developed by expert physicians and pharmacists in the three diseases
(HIV, TB and Malaria). The questions covered the clinical management of HIV/AIDS, Tuber-
culosis and Malaria and the ADRs associated with the use of antiretroviral, anti-tuberculosis
and anti-malaria drugs. The questionnaire also assessed the knowledge of Nigeria’s ADR
reporting and pharmacovigilance system.
Prior to the commencement of the workshop, the questionnaire was administered for an
hour (pre-test). At the end of the workshop, which was five days after the pre-test, the same
questionnaire was re-administered (post-test). To minimize measurement biases, the ques-
tionnaire was withdrawn immediately after the pre-test and participants were not warned the
questionnaire would be re-administered after the workshop. Participants did not also know
the result of the pre-test until after the post-test. The pass mark for the pre and post-tests was
45%.
Individual case safety reports submission. The correctness and completeness of the
ICSR and the quantities submitted online were assessed. All submitted ICSRs were manually
checked for correctness and completeness and the total number of correctly completed forms
were counted and recorded in each cycle. The number of ICSRs submitted within seven
months were summed up and compared with the amount that would have been submitted by
the national health workforce in seven months in 2015.
Pharmacovigilance committees activated and training of health facility staff by partici-
pants. To assess the two variables, participants were given a spreadsheet for recording their
step-down activities after the workshop. The spreadsheet included the following variables:
a. Status of the health facility
b. Date of training
c. Description of training
d. Objectives of the training
e. Mode of delivery of training content
f. Number of doctors, nurses and pharmacists in attendance
g. Number of Pharmacovigilance Committees activated
h. Involvement of hospital management
i. Collaboration with a pharmaceutical company in the training
j. Collaboration with NAFDAC.
Addressing the under-reporting of adverse drug reactions in public health programs
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The completed spreadsheets were submitted to NAFDAC online at different times but not
later than 10th December, 2016. We extracted the number of health facility staff trained and
the number of Pharmacovigilance Committees’ activated into a template for analysis.
Statistical analysis
We applied descriptive statistics (mean, percentage and summation) in the analysis of the bio-
demographic data and primary and secondary outcomes. The overall outcome of the model
was analyzed by calculating the percentage increase in ADR submission using the arithmetic
formula: T-M/M100 [Where T = total number of ICSRs submitted by the participants in
seven months; M = total number of ICSR submitted by the national health workforce in seven
month]. According to NAFDAC, in 2015, the over 323,941 national health workforce submit-
ted 1,385 ICSRs (refer to Figure B in S1 File), equivalents to 805 ICSRs in seven months. The
3000 ICSRs (T) (submitted by the participants) and 805 ICSRs (M) were plucked into the
arithmetic formula to determine the percentage increase in ICSRs submission.
Participants gain in knowledge was analyzed by calculating the difference between the
mean pre-test and post-test scores. Summation was applied in analyzing the number of ICSR
submitted by the participants, health staff trained by the participants and Pharmacovigilance
Committees activated.
Results
Two hundred and forty seven candidates applied for the course, 56 met the selection criteria
and were invited for the workshop but one person could not make it leaving 55 participants,
equivalent to 98.2% (55/56) participating rate. Participants’ characteristics are presented in S1
Table. Participants without a previous training in pharmacovigilance were more in number
compared with participants that have attended pharmacovigilance training (s) in the past [39
(71%) vs 16 (29.1%)].
S2 Table compares the difference in the mean scores (gain in knowledge) among the partic-
ipants. Participants more than 40 years (9.4 [SD = 7.0]), Pharmacists (8.5 [SD = 7.4]), and
Nurses (7.6 [SD = 6.4]), participants from the Roll Back Malaria program (9.3 [SD = 8.8]) and
those without previous training (9.5 [SD = 7.8]), appeared to gain knowledge more than par-
ticipants from other groups.
The outcomes of the model are presented in the S3 Table. Participants demonstrated a sig-
nificant gain in knowledge (20.4 vs 27.8 (P value < 0.001) and submitted 3000 ICSRs with
100% correctness and completeness. Compared with the 805 ICSRs submitted by more than
323,941 healthcare workers in the general population who were not SPHAR-TI trained, the
percentage increase in ICSRs submission was 273%. Participants were also able to indepen-
dently train 2,937 healthcare workers and activated 46 Pharmacovigilance Committees.
Discussion
The major finding of this evaluation is the significant gain in knowledge observed among the
participants generally. NAFDAC’s concordance on the effectiveness of the model to signifi-
cantly improve the reporting of ADRs in Nigeria (Figure B in S1 File) buttresses this observa-
tion and underscores the potential viability of the model to improve the reporting of ADRs in
public health programs. Furthermore, the positive outcome achieved when NAFDAC tested
the model in the training of 600 healthcare workers from ten states in Nigeria (Figure B in S1
File), suggests that the model can be replicated in countries facing similar challenge of under-
reporting of ADRs with Nigeria.
Addressing the under-reporting of adverse drug reactions in public health programs
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We also observed four additional outcomes. Firstly, participants developed the capacity to
detect and accurately report ADRs including the serious ADRs such as Stevens Johnson Syn-
drome (SJS) and Bilateral Gynaecomastia (BG). Secondly, the rate of ADR reporting increased
by 273%, when compared with the average reporting rate in the general population over the
past 12 years. This finding is consistent with the findings from previous studies that examined
the impact of training at improving the reporting of ADRs [31, 59]. Thirdly, participants were
able to train their peers, thus, they increased the number of healthcare workers for pharmacov-
igilance service delivery particularly in the communities. In addition, participants developed
the capacity to activate Pharmacovigilance Committees in their various health facilities. This is
a feat NAFDAC has persistently encouraged in an effort to boost the reporting of ADRs in
Nigeria.
We also observed two unintended outcomes of the application of the SPHAR-TI’s model.
The first is the detection and reporting of SJS and BG by some participants. SJS is a fatal ADR
associated with the use of Nevirapine, a popular antiretroviral drug that constitutes the back-
bone of first line antiretroviral regimen. This finding confirms that Nigerians are also suscepti-
ble to the SJS of Nevirapine as reported in other climes. Further analysis of the submitted
ICSRs might reveal other life threatening ADRs in the Nigerian population, which the
National Agency for the Control of AIDS (NACA) need to pay close attention to. The second
outcome is the interplay of several factors resulting to the increase in the reporting of ADRs.
The model combined at least six factors: training, mobilization of participants with resources
(refer to Figures A-D in S2 File), a practical reporting system, monitoring and evaluation and
providing feedbacks and effective leadership. There is no gainsaying in concluding that train-
ing alone without the other factors could not have yielded the results we have reported. Per-
haps, the reason Nigeria and other countries are not able to significantly address the challenge
of under-reporting of ADRs despite the abundance of training may be the over-reliance on
training alone without the other factors.
We observed a surprised finding in the evaluation (S3 Table). Participants without prior train-
ing tended to gain knowledge more than those who have attended pharmacovigilance trainings.
The same tendency was observed among the health care workers, with pharmacists and nurses
gaining knowledge more than the medical doctors. We do not have a viable reason for this but we
suspect that personal commitment and seriousness may have led to the difference.
The model holds an important lesson for sub-Saharan Africa (SSA), which has the largest
public health programs treating millions of people with HIV, Tuberculosis and Malaria. Cur-
rently, over 20 million people must be placed on antiretroviral drugs according to the new
WHO treatment guidelines for HIV [60]. The risk of “antiretroviral therapy associated ADRs”
is expected to be higher in this region than any other region in the world. Evidence from stud-
ies conducted in developed countries where antiretroviral therapy has been offered for many
years have reported a rise of cardiometabolic disorders like type 2 diabetis mellitus and cardio-
vascular disease [61–65], which have long been associated with the antiretroviral medications.
In the Drug Resistant Tuberculosis public health program, hearing loss associated with the use
of the injectable aminiglycosides (Amikacin and Kanamycin) is a major clinical challenge [66–
67] and yet, thousands of patients are using these drugs in the communities. As sub-Saharan
African countries continue to scale-up public health treatment programs in a wider global
effort to end HIV and Tuberculosis, the prevalence of ADRs will continue to increase, justify-
ing the need for the training of healthcare providers for ADRs reporting.
Another factor that favors the training of healthcare providers for ADR reporting, which
justifies the use of the SPHAR-TI model, is the acute shortage of healthcare workers in Africa.
The “Brain Drain” report by Rebecca Coombes showed that the number of healthcare workers
in many African countries is shrinking [68]. Ghana with a total population of 20 million
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people has only 1500 medical doctors and more than two-third of young Ghanaian doctors
leave the country within three years of graduation. In Mozambique, a nation of similar size
with Ghana, there are only 500 medical doctors [68]. Malawi has a worse situation; there are
12 million people but only 350 medical doctors are available to cater for all the health needs
including the reporting of ADRs [68]. Nigeria appears to have the highest density of healthcare
workers in Africa [37–54] but the large population size and the lack of capacity for reporting
ADRs are major constrains. However, the training of healthcare workers as has been shown in
several studies can improve the reporting of ADRs. The WHO in its 2013 report on “research
for universal health coverage”, highlighted the need for training of healthcare workers in pub-
lic health programs close to the supply and demand side of health services [69]. The structured
pharmacovigilance capacity building model that we have evaluated addresses this gap in
response to the WHO recommendation.
An important piece of information the SPHAR-TI model has demonstrated is that short
training alone is not sufficient to stem the tide of under-reporting of ADRs. In fact, most devel-
oping countries, including Nigeria, provide trainings to healthcare workers to boost the
reporting of ADRs but the crisis of under-reporting is not going away. What may be lacking
are some of the factors the SPHAR-TI model seems to illustrate, which include: poor mobiliza-
tion of healthcare providers, a weak monitoring and evaluation with complete absence of feed-
back mechanisms when ICSRs are submitted to central regulatory authorities, lack of a clear
and practical means of submitting ICSRs, lack of private-public collaboration, weak leadership
and low motivation of the workforce. If all these factors are combined appropriately, the
reporting of ADRs could significantly increase.
The model has some limitations that need to be considered alongside the positive outcomes.
The participants were practicing doctors, nurses and pharmacists with some experience in the
pharmacotherapy of AIDS, tuberculosis and malaria. This knowledge may have contributed to
the knowledge gained through the SPHAR-TI training. This argument may however not hold
true because the medical doctors expected to have the highest level of knowledge and should
have demonstrated higher scores in the post-test compared to the pharmacists and nurses actu-
ally scored less. The age of the participants is another factor; majority of the participants were
mid-career professionals occupying lower positions of responsibilities and were likely to be less
busy and quick learners. Elderly people with many social and professional responsibilities and
perhaps with a “slow to learn” disposition would probably have performed poorly. But again,
the results in S2 Table demonstrate that participant over 40 years scored higher marks than the
younger people within the age bracket of 30–39 years. Overall, the long term impact of the
model need to be assessed; our findings in this study are only limited to the period of evaluation,
which is between 10 to 12 months. However, despite these limitations, the SPHARTI model has
provided an option for improving the reporting of ADRs in resource limited settings.
We are recommending the use of the SPHAR-TI’s model to minimize the worrisome
under-reporting of ADRs in the developing world. As stated earlier, under-reporting of ADRs
prevents drug safety monitoring and regulation, which adds to the disease burden and mortal-
ity. Nigeria and other developing countries may not be able to absorb additional health chal-
lenges caused by ADRs as these countries are already overstretched by communicable and
non-communicable diseases. The SPHAR-TI model may be an effective approach that would
complement existing models of ADRs reporting in Africa and elsewhere.
Conclusion
The systematic and output driven training and follow-up of healthcare providers had a positive
impact on the reporting of ADRs. The SPHAR-TI principles effectively contributed to the
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success of the model and are recommended to institutions or organizations providing pharma-
covigilance services in Africa and other regions with similar settings.
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